Cryptorchidism

Testicular Cancer - Global Pipeline Insights, 2022: Featuring Sanofi, Seagen, BioNTech, Context Therapeutics & Leadartis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Consumer, Health, Men, Clinical Trials, Oncology, Physical examination, Testicular cancer, News, Prednisone, Ageing, Tubulin, Survival rate, Prognosis, Route, Prostate cancer, Sanofi, European Medicines Agency, Complex, Microtubule, Cell cycle, II, Administration, BioNTech, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cryptorchidism, Discovery, Epidemiology, Interphase, FDA, Cancer, SE, Knowledge, Carlos Roa, CLDN6, Route of administration, CAR, Risk, Metaphase, History, Food, Apoptosis, Therapy, Patient, RNA, Cabazitaxel, Clinical trial, EMA, Docetaxel, Dietary supplement, Vaccine, Pharmaceutical industry, Testicle

This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.

Key Points: 
  • This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.
  • Testicular cancer is one of the most common malignancies in men aged 15 to 45 years.
  • Complex environmental and genetic factors are involved in the development of testicular cancer; common risk factors include cryptorchidism, family history of testicular cancer, personal history of testicular cancer in the contralateral testis, age, and ethnicity.
  • Testicular Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Human Chorionic Gonadotropin Market Report 2022: Oligospermia Supports Demand for HCG Drugs and Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 29, 2022
Health, Other Health, Urine, Government, Ovulation, Egg, Oligospermia, Fertility, Infertility, Fertilisation, Female, DNA, Growth, Patient, Degenerative disease, Pregnancy, HCG, Gonadotropin, Safety, Cryptorchidism, Human chorionic gonadotropin, Hormone, Incidence, Woman, Renewable energy, Agriculture, Birth control

The "Global Human Chorionic Gonadotropin Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Human Chorionic Gonadotropin Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Global Human Chorionic Gonadotropin Market is having an exponential growth rate of 7.5% from 2022 to 2030.
  • For the purpose of this report, the technology segment of the global human chorionic gonadotropin market has been segmented into natural source extract and recombinant DNA technology.
  • Asia-Pacific is expected to be the most potential regional market for human chorionic gonadotropin market by 2030.

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)

Retrieved on: 
Thursday, July 28, 2022
Pulmonary embolism, Liver, Edema, Neoplasm, BPH, Hypercalcaemia, Capsule, Testosterone, Birth, LHRH, Woman, Gynecomastia, Radiation, Sleep apnea, Gonadotropin, Trauma, Cardiovascular disease, Androgen, DVT, Luteinizing hormone, Prostate cancer, Orchiectomy, FSH, Cryptorchidism, Primary, Risk, Adult, Deep vein thrombosis, Hypogonadism, T4, Chronic lung disease, Safety, Cancer, Orchitis, VTE, Thyroid, Hypergonadotropic hypogonadism, Suicidal ideation, Heart, Klinefelter syndrome, CIII, Patient, PE, Thyroxine-binding globulin, Serum, Breast cancer, Man, Blood pressure, Depression, Spermatogenesis, Obesity, Methyltestosterone, BP, MACE, Birth control, Dietary supplement, Pharmaceutical industry, Medical imaging

NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for additional claims that cover its oral testosterone replacement product, JATENZO (testosterone undecanoate).

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patients baseline cardiovascular risk and ensure blood pressure is adequately controlled.
  • Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

Retrieved on: 
Monday, May 9, 2022
T4, LHRH, Birth, Androgen, Methyltestosterone, CIII, Hypergonadotropic hypogonadism, Orchitis, Hypogonadism, Blood pressure, Woman, Thyroid, Neoplasm, Spermatogenesis, Liver, MACE, Breast cancer, Deep vein thrombosis, DVT, Cardiovascular disease, Radiation, Chronic lung disease, Suicidal ideation, Patient, Trauma, Pulmonary embolism, Gynecomastia, Testosterone, Sleep apnea, Edema, Heart, Luteinizing hormone, Risk, Gonadotropin, Cancer, VTE, Obesity, Primary, Klinefelter syndrome, Orchiectomy, FSH, Adult, Thyroxine-binding globulin, PE, Cryptorchidism, Prostate cancer, Hypercalcaemia, Serum, BP, BPH, Depression, Capsule, Man, Safety, Birth control, Dietary supplement, Pharmaceutical industry, Medical imaging

NORTHBROOK, Ill., May 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be presented in the form of an abstract at the 2022 American Urological Association Annual Meeting taking place at the New Orleans Ernest N. Morial Convention Center in New Orleans May 13-16, 2022.

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patients baseline cardiovascular risk and ensure blood pressure is adequately controlled.
  • Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA

Retrieved on: 
Thursday, October 14, 2021
Risk, Androgen, Suicidal ideation, DVT, Luteinizing hormone, Primary, Liver, Gynecomastia, Heart, T4, Trauma, Thyroid, MACE, FSH, Man, Hypogonadism, Radiation, Breast cancer, Cancer, Testosterone, Thyroxine-binding globulin, Klinefelter syndrome, Adult, Serum, Safety, Cardiovascular disease, Birth, Capsule, Woman, Gonadotropin, LHRH, PE, BP, VTE, Pulmonary embolism, Patient, Spermatogenesis, Sleep apnea, Orchitis, Edema, Methyltestosterone, BPH, Hypergonadotropic hypogonadism, Blood pressure, Chronic lung disease, Neoplasm, Prostate cancer, Deep vein thrombosis, Hypercalcaemia, Cryptorchidism, Orchiectomy, Depression, Obesity, CIII, Birth control, Dietary supplement, Pharmaceutical industry, Medical imaging

NORTHBROOK, Ill., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new real-world experience data for JATENZO® (testosterone undecanoate) will be presented at the 22nd Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA), taking place at The Westin Kierland in Scottsdale, Arizona, October 21-24, 2021.

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patients baseline cardiovascular risk and ensure blood pressure is adequately controlled.
  • Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

AUA Releases New Clinical Guideline for Diagnosis and Treatment of Testicular Cancer

Retrieved on: 
Thursday, May 2, 2019
Men's Health, RTT, Organ systems, Medical specialties, Scrotum, Mammal male reproductive system, Cryptorchidism, Testicle, Testicular cancer, Urology, Cancer, Testicular microlithiasis

LINTHICUM,Md., May 2, 2019 /PRNewswire/ -- Today,the American Urological Association (AUA), a leading global urology association, released a new clinical guideline on the diagnosis and treatment of early stage testicular cancer.

Key Points: 
  • LINTHICUM,Md., May 2, 2019 /PRNewswire/ -- Today,the American Urological Association (AUA), a leading global urology association, released a new clinical guideline on the diagnosis and treatment of early stage testicular cancer.
  • Testicular cancer is the most common cancer among men ages 20 to 40.
  • Although it is a less common form of cancer, about 9,600 men in the US will be told this year they have the disease.
  • Men who were born with cryptorchidism (undescended testicle) have a greater chance of being diagnosed with testicular cancer, as are men with a family history or men with a personal history of testis cancer.

Almost two thirds of Canadian men aged 18-34 don't know their testicular cancer risk

Retrieved on: 
Tuesday, April 2, 2019
Men's Health, Organ systems, RTT, Mammal male reproductive system, Scrotum, Anatomy, Testicle, Cryptorchidism, Testicular self-examination, Testicular cancer, Cancer, Testicular microlithiasis

Testicular cancer is the most common cancer in young men, and the charity is now urging men in the at-risk age group to carry out regular self-checks as early diagnosis is key to successful treatment.

Key Points: 
  • Testicular cancer is the most common cancer in young men, and the charity is now urging men in the at-risk age group to carry out regular self-checks as early diagnosis is key to successful treatment.
  • Testicular cancer strikes early so checking regularly and knowing what to look for is crucial."
  • However, the poll of 474 Canadian men conducted by YouGov, also found that 57% of men in the at-risk age group (aged 18-34) didn't know or are unsure how to perform a testicular self-examination.
  • Those most at risk are men who had undescended testes at birth, or those with a relative who has diagnosed with testicular cancer.

The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025

Retrieved on: 
Tuesday, October 23, 2018
Endocrine system, Anatomy, Human reproduction, Scrotum, Testicle, Fertility medicine, Fertility, Male genital disorders, Cryptorchidism, Hypogonadism, Infertility, Male infertility

It is widely being used to treat infertility-related problems in women as well as increase sperm count in men.

Key Points: 
  • It is widely being used to treat infertility-related problems in women as well as increase sperm count in men.
  • Moreover, it is used to treat cryptorchidism in young boys, a condition when the testicles have not dropped down into the scrotum normally.
  • Significant surge in infertility issues among men & women and increase in prevalence of hypogonadism in geriatric population drive the growth of the global hCG market.
  • A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.